Pub. Date : 2019 Nov
PMID : 31267520
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib. | ibrutinib | C-X-C motif chemokine receptor 4 | Homo sapiens |
| 2 | CXCR4 mutations are detected in 30-40% of patients with WM and associate with lower rates of response and shorter PFS to ibrutinib therapy. | ibrutinib | C-X-C motif chemokine receptor 4 | Homo sapiens |
| 3 | Our results suggest different response and PFS rates to ibrutinib for WM patients with CXCR4NS and CXCR4FS , and advocate in favour of CXCR4 mutational testing as well as CXCR4-directed therapy. | ibrutinib | C-X-C motif chemokine receptor 4 | Homo sapiens |
| 4 | Our results suggest different response and PFS rates to ibrutinib for WM patients with CXCR4NS and CXCR4FS , and advocate in favour of CXCR4 mutational testing as well as CXCR4-directed therapy. | ibrutinib | C-X-C motif chemokine receptor 4 | Homo sapiens |
| 5 | Our results suggest different response and PFS rates to ibrutinib for WM patients with CXCR4NS and CXCR4FS , and advocate in favour of CXCR4 mutational testing as well as CXCR4-directed therapy. | ibrutinib | C-X-C motif chemokine receptor 4 | Homo sapiens |